Phentermine vs Wegovy and Zepbound: older vs newer weight-loss drugs

Quick answer: Phentermine (a pill, approved in 1959) and Wegovy or Zepbound (weekly injections, approved 2021 and 2023) both help people eat less, but they are very different tools. Phentermine is cheap, fast-acting and meant for short-term use; it works by stimulating the nervous system. Wegovy (semaglutide) and Zepbound (tirzepatide) mimic gut hormones, produce considerably larger average weight loss in trials, and are designed for long-term treatment, but they cost far more, can cause digestive side effects and are often hard to get covered. Which is “better” depends on your health, budget, goals and risk profile.

Inside this comparison

1. Two generations of weight-loss medicine
2. How each drug works
3. Head-to-head scorecard
4. Effectiveness: what the trials found
5. Side effects and safety
6. Who each option tends to suit
7. Cost, coverage and access
8. What happens when you stop
9. Can they be combined or sequenced?
10. A five-question decision guide
11. Frequently asked questions

Two generations of weight-loss medicine

For decades, prescription options for obesity were limited, and most were modest in effect. Phentermine, first approved in the United States in 1959, was the workhorse: a small, inexpensive pill that reduces appetite. The older era also produced drugs that were withdrawn for safety reasons, which shaped the cautious attitude many doctors still have toward weight-loss pharmacology.

The picture changed once researchers learned how gut hormones signal fullness to the brain. Semaglutide, a GLP-1 receptor agonist, was first marketed for type 2 diabetes and then approved at a higher dose as Wegovy for chronic weight management. Tirzepatide, which activates both GLP-1 and GIP receptors, followed as Mounjaro for diabetes and Zepbound for weight management. These medicines opened the door to average weight loss that earlier drugs seldom reached.

That does not make phentermine obsolete. It remains one of the most prescribed anti-obesity medicines in the United States largely because it is inexpensive and familiar. Our overview of alternatives to phentermine and our guide to Wegovy alternatives map out the broader landscape.

How each drug works

Phentermine: turning down hunger via the nervous system

Phentermine increases release of norepinephrine, with smaller effects on dopamine and serotonin, in areas of the brain that influence appetite. The result is less hunger and sometimes a mild energy lift. Because the same signalling affects the cardiovascular system, side effects include higher pulse, raised blood pressure, dry mouth and trouble sleeping. If cardiovascular effects are your main concern, read phentermine and blood pressure: risks and monitoring.

Wegovy: mimicking GLP-1

Semaglutide imitates glucagon-like peptide-1, a hormone released after eating. It acts on the brain to reduce appetite and cravings, slows stomach emptying so you feel full longer, and enhances insulin release when glucose is high. It is injected once a week, with the dose raised gradually over several months to limit nausea.

Zepbound: a dual-action approach

Tirzepatide activates both GLP-1 and GIP receptors. The addition of GIP signalling is believed to contribute to greater appetite reduction and metabolic effects, although the exact mechanisms are still being studied. It is also a once-weekly injection with stepwise dose escalation.

Head-to-head scorecard

The table below summarises key differences in plain language. Figures are approximate and drawn from published trials and prescribing information; always check the current label.

Feature	Phentermine	Wegovy (semaglutide)	Zepbound (tirzepatide)
Drug class	Sympathomimetic amine (appetite suppressant)	GLP-1 receptor agonist	Dual GIP / GLP-1 receptor agonist
How it is taken	Daily oral tablet or capsule	Weekly injection (an oral semaglutide option for weight management has also been introduced; check current availability)	Weekly injection
First approved	1959 (US)	2021 for weight management	2023 for weight management
Labelled duration	Short-term (weeks)	Long-term, chronic use	Long-term, chronic use
Controlled substance?	Yes, Schedule IV	No	No
Typical trial weight loss	Smaller average; often around 5% to 7% over about 6 months in older trials	About 15% at 68 weeks (STEP 1)	About 15% to 21% at 72 weeks by dose (SURMOUNT-1)
Most common side effects	Dry mouth, insomnia, palpitations, higher BP, nervousness	Nausea, diarrhoea, vomiting, constipation	Nausea, diarrhoea, vomiting, constipation
Key warnings	Avoid in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use, pregnancy	Boxed warning: thyroid C-cell tumours (rodents); pancreatitis, gallbladder disease, kidney injury from dehydration	Same class warnings as Wegovy
Typical cost	Low (generics)	High without coverage	High without coverage
Extra approved benefits	None beyond weight management	Cardiovascular risk reduction in adults with established heart disease and excess weight	Obstructive sleep apnea in adults with obesity

Prices, indications and availability change frequently. Confirm against the manufacturer’s current information and your insurer before deciding.

Effectiveness: what the trials found

Wegovy

In the STEP 1 trial, adults with overweight or obesity who took semaglutide 2.4 mg weekly alongside lifestyle support lost on average about 15% of their body weight at 68 weeks, compared with roughly 2% for placebo. The trial was published in the New England Journal of Medicine. A large outcomes study, SELECT, also found reduced rates of major cardiovascular events in people with established heart disease and excess weight who did not have diabetes.

Zepbound

In SURMOUNT-1, participants without diabetes lost on average roughly 15% (5 mg), 19% (10 mg) and 21% (15 mg) of body weight at 72 weeks, versus about 3% on placebo. See the NEJM report. A later head-to-head study funded by the manufacturer of Zepbound reported greater average weight loss with tirzepatide than with semaglutide over a bit more than a year, which is consistent with what the separate trials suggested.

Phentermine

Evidence for phentermine alone is older and generally comes from shorter or smaller studies. Average losses are meaningful for many people, with some losing 5% or more of body weight within a few months, but there is a wide spread. Evidence of long-term benefit and long-term safety is much thinner than for the newer injectables, one reason the label emphasises short-term use. To understand why that limit exists, read how long can you take phentermine?

Reading the numbers sensibly

• Trial averages hide variety: some people lose far more than the mean, others much less.
• Trials include structured diet and activity counselling. Results without support are usually smaller.
• Different trial populations (with or without diabetes) respond differently. People with type 2 diabetes generally lose less weight on every drug.
• Percent loss is not the only goal. Better blood sugar, blood pressure, joint pain, sleep apnea and fertility often matter more to patients.

Side effects and safety

Phentermine: the “wired” profile

Typical complaints include dry mouth, trouble sleeping, jitteriness, constipation, headache, a faster pulse and increased blood pressure. Serious concerns centre on the heart and blood vessels, and on rare psychiatric effects. Because it is stimulant-like, misuse potential is why it is scheduled as a controlled drug. Sleep disruption is so common that we wrote a separate guide, phentermine and insomnia: why it happens and how to manage it.

Wegovy and Zepbound: the “queasy” profile

Gastrointestinal effects dominate: nausea, vomiting, diarrhoea, constipation, abdominal pain and reflux. They tend to be worst during dose escalation and often fade, but they lead some people to stop. Less common but important risks listed on labelling include pancreatitis, gallbladder problems (gallstones are more likely with rapid weight loss), kidney injury linked to dehydration, changes in vision for people with diabetic retinopathy, and rare allergic reactions. Both carry a boxed warning about thyroid C-cell tumours seen in rodents; they should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Muscle, nutrition and hair

Any significant weight loss can include loss of lean tissue, and rapid loss can trigger temporary hair shedding or nutrient shortfalls if intake is very low. With GLP-1 therapy, where appetite can fall sharply, protein targets and resistance training become especially important. Practical help is in our guide to protein powders for weight loss and our 7-day diet plan for weight loss.

Who should not use each

• Phentermine: history of heart disease or stroke, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, drug misuse history, MAOI use within 14 days, pregnancy or breastfeeding.
• Wegovy / Zepbound: personal or family history of medullary thyroid cancer or MEN 2, pregnancy, prior serious allergy to the ingredients. Extra caution with history of pancreatitis, gallbladder disease or severe gastroparesis.

Who each option tends to suit

These are generalisations, not prescriptions. Your own clinician decides based on your history.

Situations that often point toward phentermine

• You need a low-cost, short-term boost and have no cardiovascular risk factors.
• Injectable therapy is unavailable, unaffordable or unacceptable to you.
• You want a bridge while waiting for coverage or supply of another medicine.

Situations that often point toward Wegovy or Zepbound

• You have a higher BMI or weight-related conditions such as type 2 diabetes, fatty liver, sleep apnea or established heart disease.
• You need sustained, long-term weight management rather than a short course.
• Stimulants are risky for you because of blood pressure, heart rhythm or anxiety.
• Your insurance or an employer programme covers it.

Situations that call for a different option altogether

• You have a personal history of medullary thyroid cancer (avoid GLP-1 class) and cardiovascular disease (avoid phentermine). Non-stimulant, non-GLP-1 options or bariatric evaluation may be considered. See Contrave vs phentermine and phentermine vs topiramate.

Cost, coverage and access

Price is where the old-versus-new gap is largest. Generic phentermine is typically inexpensive, even paid for out of pocket, and may need only short-interval prescriptions. Wegovy and Zepbound have historically carried high list prices, and coverage for obesity (as opposed to diabetes) varies by insurer, employer and, in the United States, by whether you are on Medicare or Medicaid. Manufacturer savings programmes, direct-to-patient pricing and telehealth channels have changed frequently, so confirm current terms rather than relying on any article, including this one.

A few practical tips:

• Ask your insurer whether anti-obesity medicines are covered, which diagnosis codes count, and whether prior authorisation or documented lifestyle attempts are required.
• Be cautious with compounded or “research” versions marketed online. Quality, dosing and legality can be uncertain; the FDA has issued warnings about unapproved products. Use only products dispensed against a valid prescription by a licensed pharmacy.
• If you are considering a telehealth route for phentermine, read how to get a phentermine prescription online to understand what a legitimate evaluation involves.
• Shortages have occurred with injectables, so ask a pharmacist about supply when planning dose escalation.

What happens when you stop

Obesity is a chronic, relapsing condition, and body weight tends to climb back after any treatment ends. Follow-up data from the semaglutide programme showed that, a year after stopping, participants regained a substantial share of the weight they had lost. Similar patterns appear with other agents. The practical meaning is that you need an exit strategy from day one.

• With phentermine, the plan usually involves a defined stop date, then maintenance habits (protein, strength training, steps, sleep). If weight rises again, discuss a different approach rather than simply re-starting without review.
• With Wegovy or Zepbound, many clinicians treat therapy like other chronic-disease medicines, continuing at a maintenance dose. If you stop, tapering, close monitoring and a robust lifestyle plan help, but regain is common.

Our guide on building a diet and exercise plan to pair with phentermine is equally useful as a foundation if you choose a GLP-1 medicine, because the habits are the part you keep.

Can they be combined or sequenced?

Doctors sometimes switch from one medicine to another when response is poor or side effects are intolerable, and a few use combinations in specialised settings. However, high-quality evidence for combining phentermine with a GLP-1 or GIP/GLP-1 drug is limited, and stacking stimulant and appetite-suppressing mechanisms can intensify side effects such as dehydration, dizziness and palpitations. Do not combine them on your own or with medicine bought from unverified sources.

A more common sequence is: start with the option that matches your risk profile; reassess at around 12 weeks; if response is under about 5% of body weight, change course. Qsymia, which blends phentermine with topiramate, is another step on the ladder, explained in how phentermine-topiramate (Qsymia) works.

What treatment actually feels like

Numbers from trials tell you little about daily life, so here is a realistic picture of what the first months often look like on each option. Experiences differ, and your own clinician’s instructions always come first.

Starting phentermine

Most people take a single tablet or capsule in the morning. Appetite often drops within days. Many notice a dry mouth, a slight edge of restlessness and, if they take it too late in the day, difficulty falling asleep. Meals feel smaller and cravings are quieter, but the effect can fade somewhat over several weeks, which is why some people feel it “stops working.” Follow-up visits tend to focus on weight, pulse and blood pressure.

Starting Wegovy or Zepbound

Treatment starts with a low dose that is stepped up roughly monthly. Early on, many people feel fuller after a few bites and may lose interest in food, alcohol or snacking. Nausea, reflux or constipation can appear after each dose increase, then ease. Eating smaller meals, avoiding greasy or very large portions, drinking fluids and stopping at the first sign of fullness make a noticeable difference. Because appetite can fall so far, it is easy to under-eat protein, so planning meals matters.

Common warning signs to report

• Phentermine: chest pain, fainting, severe headache, racing heartbeat, swelling in the legs, mood changes or agitation that is out of character.
• Wegovy / Zepbound: severe or persistent abdominal pain (especially radiating to the back, with or without vomiting), yellowing of skin or eyes, persistent vomiting or inability to keep fluids down, a lump or swelling in the neck, hoarseness or difficulty swallowing, and signs of an allergic reaction.

The part no medicine replaces

All three medicines were tested alongside reduced-calorie eating and physical activity. The drug lowers the barrier; habits decide how much you gain from it and how well you keep it. A few principles apply no matter which you choose:

• Prioritise protein. Aim to include a protein source at each meal to protect muscle. Targets differ by person, so ask a dietitian for numbers suited to your kidneys and goals.
• Lift something. Two sessions of resistance training weekly help preserve lean mass while the scale moves.
• Move daily. The CDC’s adult activity guidelines suggest at least 150 minutes of moderate activity each week plus muscle-strengthening work.
• Protect sleep. Short or broken sleep increases hunger hormones and undermines results. Our guides on why sleep matters for health and how to cure insomnia are good starting points.
• Choose whole foods. Fibre-rich meals ease constipation, which is common on all three medicines. See foods that help prevent obesity and the Mediterranean diet for patterns that suit long-term use.
• Track more than weight. Waist circumference, strength, energy, blood pressure and lab results show progress when the scale stalls.

If your appetite is very low, watch for dehydration and under-eating. Fatigue, dizziness, dark urine and headaches can be early signs. Contact your care team if they persist.

A five-question decision guide

Use these questions to prepare for your appointment. They will not give you a verdict, but they will clarify what to discuss.

1. What is my cardiovascular risk? Elevated blood pressure, heart disease or arrhythmia favours non-stimulant options.
2. How much weight and how much health benefit am I aiming for? Larger goals and obesity-related complications often justify the more powerful injectables.
3. How long will I need treatment? A short push suits phentermine; a lifelong approach suits GLP-1 type therapy.
4. What can I realistically afford and access? Include dose-escalation costs and the cost of continuing after the first few months.
5. How do I handle side effects? If nausea worries you more than sleeplessness, or the reverse, that matters.

Frequently asked questions

Is phentermine as effective as Wegovy or Zepbound?

On average, no. Trials of semaglutide and tirzepatide report larger and more sustained average weight loss than is typical for phentermine, though individual results vary and phentermine can still work well for some people.

Which is safer, phentermine or Wegovy?

They carry different risks. Phentermine’s concerns are mainly cardiovascular and nervous-system effects and misuse potential; Wegovy’s are mainly gastrointestinal, gallbladder and pancreatic issues, plus a boxed thyroid warning. Safety depends on your health profile.

Can I switch from phentermine to Zepbound?

Many people do, usually after a review with their prescriber. There is no required wash-out for efficacy reasons, but your clinician will consider side effects, dosing and your goals.

Why is phentermine only approved for a few weeks?

It was approved when trials were short, and long-term safety and effectiveness data are limited. Many clinicians use it for around 12 weeks, sometimes longer in selected patients.

Do Wegovy and Zepbound lower blood pressure?

In trials, average systolic blood pressure fell modestly, in line with weight loss. Individual responses differ, and people on blood pressure medicines may need adjustments.

Will I regain weight after stopping?

Many people do with every weight-loss medicine, which is why maintenance planning matters.

Are compounded semaglutide or tirzepatide products safe?

Quality and dosing vary, and regulators have warned about unapproved or counterfeit versions. Choose FDA-approved products from licensed pharmacies, under medical supervision.

Is there an oral GLP-1 pill for weight loss?

Oral GLP-1 options have been progressing through regulatory review and entering the market. Ask your clinician or check the manufacturer’s information for what is currently approved and available in your country.

The bottom line

Phentermine is the affordable, short-term, stimulant-based tool. Wegovy and Zepbound are the newer, more potent, hormone-based tools that treat obesity as a chronic condition, with higher costs and different side effects. The right choice is rarely about which medicine is newer; it is about your heart health, your goals, your budget and your willingness to commit to a long-term plan. Bring that information to a clinician who can examine the whole picture.

Medical disclaimer: This article is for general education only and is not medical advice. Weight-loss medicines have risks and are not suitable for everyone. Consult a licensed healthcare professional before starting, stopping or changing any medication.

Sources and further reading

• NEJM: Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
• NEJM: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
• NIDDK: Prescription medications to treat overweight and obesity
• DailyMed: Wegovy prescribing information
• DailyMed: Zepbound prescribing information